Isoindolinone kinase inhibitors
AssigneeAbbott Laboratories
InventorsMichael L. Curtin, Steven K. Davidsen, Robin R. Frey, Howard R. Heyman, James H. Holms, Michael Michaelides, Douglas H. Steinman
Life of this patent
Estimating the term…
Abstract
Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
Claims2
A method for inhibiting a protein kinase in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I)
- or a therapeutically acceptable salt thereof, wherein
- R1 is selected from the group consisting of hydrogen and alkyl;
- R2 is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NRcRd;
- and
- one of R3 and R4 is A-X-R5 and the other is hydrogen;
- wherein A-X-R5 is drawn with its left end attached to the parent molecular moiety;
- R5 is selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
- A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl;
- and
- X is selected from the group consisting of O, NRa, N(Ra)C(S)N(Rb), (CH2)mN(Ra)C(O)N(Rb)(CH2)n, CH2C(O)N(Ra), and N(Ra)C(O), wherein Ra and Rb are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R5.
A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I)
- or a therapeutically acceptable salt thereof, wherein
- R1 is selected from the group consisting of hydrogen and alkyl;
- R2 is selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkyl, carboxyalkoxy, carboxyalkyl, halo, haloalkyl, heterocyclylalkoxy, hydroxy, nitro, and —NRcRd;
- and
- one of R3 and R4 is A-X-R5 and the other is hydrogen;
- wherein A-X-R5 is drawn with its left end attached to the parent molecular moiety;
- R5 is selected from the group consisting of aryl, heteroaryl, and heterocyclyl;
- A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, haloalkoxy, and haloalkyl;
- and
- X is selected from the group consisting of O, NRa, N(Ra)C(S)N(Rb), (CH2)mN(Ra)C(O)N(Rb)(CH2)n, CH2C(O)N(Ra), and N(Ra)C(O), wherein Ra and Rb are independently selected from the group consisting of hydrogen and alkyl, m and n are independently 0 or 1, and wherein each group is drawn with its left end attached to A and its right end attached to R5.
Dependencies are inferred from the claim text.